lecanemab

Alzheimer’s drugs are not the breakthrough promised: Review

A review of more than 20,000 participants found that plaque‑clearing Alzheimer’s drugs offer minimal clinical benefit and carry notable safety…

Year in review: Dementia breakthroughs

Dementia has surpassed heart disease to become the leading cause of death in Australia, a statistic confirmed by the Australian…

Lecanemab approved by TGA

A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator in a major development…

TGA doubles down on rejection of Alzheimer’s drug

The Australian Therapeutic Goods Administration (TGA) has confirmed its decision not to register Alzheimer's disease drug lecanemab (LEQEMBI). Lecanemab is…